Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (ASCO 2011, Plenary Session, Abstract LBA4)
Research output: Contribution to journal › Article › peer-review
Bibliographical metadata
| Original language | English |
|---|---|
| Pages (from-to) | LBA4-LBA4 |
| Number of pages | 1 |
| Journal | Journal of Clinical Oncology |
| Volume | 29 |
| Issue number | Supplement 15 |
| DOIs | |
| Publication status | Published - 20 May 2011 |